Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$776.75
-0.6%
$762.03
$399.26
$800.78
$738.04B0.343.07 million shs2.76 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.17
+6.0%
$26.87
$25.20
$40.37
$145.07B0.6142.56 million shs97.47 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.62%+6.08%+2.21%+17.62%+92.17%
Pfizer Inc. stock logo
PFE
Pfizer
+6.09%+3.47%-1.91%-0.40%-30.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.5514 of 5 stars
2.43.02.54.02.61.72.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9777 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$757.95-2.42% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3333.73% Upside

Current Analyst Ratings

Latest PFE and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$900.00 ➝ $1,001.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$850.00 ➝ $900.00
5/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$850.00 ➝ $892.00
4/30/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00 ➝ $885.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
(Data available from 5/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B21.63$8.04 per share96.66$11.44 per share67.90
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.63$3.16 per share8.61$15.81 per share1.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80133.9241.991.6115.36%51.22%9.94%8/13/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3675.479.811.163.62%10.88%4.91%N/A

Latest PFE and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024Q1 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.53$2.58+$0.05$2.68$8.94 billion$8.77 billion      
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.67%+15.15%89.66%10 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.18%+2.57%466.67%15 Years

Latest PFE and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE and LLY Headlines

SourceHeadline
Q1 2024 Pfizer Inc Earnings Call TranscriptQ1 2024 Pfizer Inc Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)Raymond James Financial Services Advisors Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)
marketbeat.com - May 1 at 11:16 PM
Pfizer stock gains 7% after earnings beat, company calls dividend securePfizer stock gains 7% after earnings beat, company calls dividend 'secure'
msn.com - May 1 at 8:39 PM
Pfizer (PFE) Q1 2024 Earnings Call TranscriptPfizer (PFE) Q1 2024 Earnings Call Transcript
fool.com - May 1 at 8:39 PM
Why Pfizer Stock Blasted More Than 6% Higher TodayWhy Pfizer Stock Blasted More Than 6% Higher Today
fool.com - May 1 at 5:55 PM
PFE Earnings: Pfizer Rises After Smashing Q1 EstimatesPFE Earnings: Pfizer Rises After Smashing Q1 Estimates
msn.com - May 1 at 3:39 PM
Pfizer (NYSE:PFE) Stock Price Up 3.8%Pfizer (NYSE:PFE) Stock Price Up 3.8%
marketbeat.com - May 1 at 1:59 PM
Pfizer Stock Gets Boost From Better-Than-Expected EarningsPfizer Stock Gets Boost From Better-Than-Expected Earnings
investopedia.com - May 1 at 1:46 PM
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance RaisedPfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
zacks.com - May 1 at 12:46 PM
Pfizer raises guidance amid cost savingsPfizer raises guidance amid cost savings
msn.com - May 1 at 10:38 AM
Pfizer Stock Rises as Outlook Rises After Earnings BeatPfizer Stock Rises as Outlook Rises After Earnings Beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue DeclinePfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
finance.yahoo.com - May 1 at 10:38 AM
Stocks to Watch Wednesday: Starbucks, Pfizer, CVS, AmazonStocks to Watch Wednesday: Starbucks, Pfizer, CVS, Amazon
finance.yahoo.com - May 1 at 10:38 AM
Pfizer raises full-year outlook, stock rises on Q1 beatPfizer raises full-year outlook, stock rises on Q1 beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to SayPfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com - May 1 at 10:35 AM
Pfizer (NYSE:PFE) Releases FY24 Earnings GuidancePfizer (NYSE:PFE) Releases FY24 Earnings Guidance
marketbeat.com - May 1 at 9:35 AM
Pfizer (PFE) Q1 Earnings and Revenues Beat EstimatesPfizer (PFE) Q1 Earnings and Revenues Beat Estimates
zacks.com - May 1 at 8:55 AM
Pfizer revenues fall 19% due to lower COVID-related product demandPfizer revenues fall 19% due to lower COVID-related product demand
proactiveinvestors.com - May 1 at 8:14 AM
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid salesPfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
cnbc.com - May 1 at 7:13 AM
Amazon, Pfizer And 3 Stocks To Watch Heading Into WednesdayAmazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
benzinga.com - May 1 at 7:01 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid decline
invezz.com - May 1 at 7:01 AM
Pfizer beats profit estimates on cost cuts, RSV vaccine salesPfizer beats profit estimates on cost cuts, RSV vaccine sales
reuters.com - May 1 at 6:50 AM
Pfizer (NYSE:PFE) Trading 0.4% Higher Pfizer (NYSE:PFE) Trading 0.4% Higher
marketbeat.com - April 30 at 3:37 PM
Pfizer and Genmab Receive FDA Approval for Cervical Cancer DrugPfizer and Genmab Receive FDA Approval for Cervical Cancer Drug
baystreet.ca - April 30 at 2:54 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.